| scholarly article | Q13442814 |
| P50 | author | Graeme Milligan | Q28468987 |
| Brian D Hudson | Q40356293 | ||
| Trond Ulven | Q40356350 | ||
| Nicola J Smith | Q57199403 | ||
| P2093 | author name string | Evi Kostenis | |
| Richard J Ward | |||
| Irina G Tikhonova | |||
| Christel Drewke | |||
| Manuel Grundmann | |||
| Johannes Schmidt | |||
| Elisabeth Christiansen | |||
| P2860 | cites work | Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids | Q24314243 |
| The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids | Q24337476 | ||
| The maximal affinity of ligands | Q24682680 | ||
| The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1 | Q27865233 | ||
| Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids | Q28189706 | ||
| Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation | Q28200878 | ||
| Molecular identification of high and low affinity receptors for nicotinic acid | Q28202556 | ||
| PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect | Q28206812 | ||
| Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors | Q28261556 | ||
| Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 | Q28509150 | ||
| Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
| Drugging challenging targets using fragment-based approaches | Q30979472 | ||
| Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides | Q34294058 | ||
| Transforming fragments into candidates: small becomes big in medicinal chemistry | Q34981076 | ||
| GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors | Q35008381 | ||
| The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target | Q36502679 | ||
| Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors | Q36880900 | ||
| The evasive nature of drug efficacy: implications for drug discovery | Q36894549 | ||
| Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. | Q37081904 | ||
| Functional selectivity in GPCR modulator screening | Q37184786 | ||
| International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions | Q37338747 | ||
| Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. | Q37504335 | ||
| Cellular assays as portals to seven-transmembrane receptor-based drug discovery | Q37553926 | ||
| 7TM pharmacology measured by label-free: a holistic approach to cell signalling | Q37578079 | ||
| Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. | Q37589701 | ||
| Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation | Q37756247 | ||
| When simple agonism is not enough: emerging modalities of GPCR ligands. | Q37775132 | ||
| Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis | Q39832093 | ||
| Locating ligand-binding sites in 7TM receptors by protein engineering. | Q40535098 | ||
| The probable arrangement of the helices in G protein-coupled receptors. | Q40872681 | ||
| Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. | Q42808008 | ||
| The minor binding pocket: a major player in 7TM receptor activation | Q42876628 | ||
| Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. | Q42937057 | ||
| Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids | Q43095402 | ||
| G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation | Q43241053 | ||
| Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor | Q44636885 | ||
| Ligand efficiency indices as guideposts for drug discovery. | Q55040766 | ||
| The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators | Q82219704 | ||
| A holistic view of GPCR signaling | Q85008509 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fatty acid | Q61476 |
| P304 | page(s) | 10628-10640 | |
| P577 | publication date | 2011-01-10 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3 | |
| P478 | volume | 286 |
| Q37227642 | A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias |
| Q39341462 | A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer. |
| Q38974288 | A cell-permeable inhibitor to trap Gαq proteins in the empty pocket conformation |
| Q28263483 | An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion |
| Q39273205 | Application of GPCR Structures for Modelling of Free Fatty Acid Receptors |
| Q51513968 | Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. |
| Q60302729 | Characterisation of small molecule ligands 4CMTB and 2CTAP as modulators of human FFA2 receptor signalling |
| Q39564257 | Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. |
| Q24338567 | Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor |
| Q47210557 | Distinctive microbiomes and metabolites linked with weight loss after gastric bypass, but not gastric banding. |
| Q37237145 | Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs |
| Q36150861 | Emerging pathogenic links between microbiota and the gut-lung axis. |
| Q41904409 | Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. |
| Q100454951 | FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells |
| Q38756670 | Fatty acid and mineral receptors as drug targets for gastrointestinal disorders |
| Q38270175 | Free fatty acid receptors as therapeutic targets for the treatment of diabetes |
| Q35766268 | Free fatty acid receptors: structural models and elucidation of ligand binding interactions |
| Q38025858 | G protein-coupled receptors for energy metabolites as new therapeutic targets |
| Q51762114 | G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. |
| Q88916668 | Gut Microbiota: FFAR Reaching Effects on Islets |
| Q38645790 | Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion. |
| Q38720041 | Identifying ligands at orphan GPCRs: current status using structure-based approaches |
| Q58687097 | Label-Free Biosensors for Cell Biology |
| Q51377037 | Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). |
| Q38014830 | Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists. |
| Q26752828 | Metabolism meets immunity: The role of free fatty acid receptors in the immune system |
| Q39855336 | Metalloprotease cleavage of the N terminus of the orphan G protein-coupled receptor GPR37L1 reduces its constitutive activity. |
| Q53077901 | Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier. |
| Q38107811 | Minireview: The effects of species ortholog and SNP variation on receptors for free fatty acids. |
| Q42703540 | Mutation analysis and molecular modeling for the investigation of ligand-binding modes of GPR84. |
| Q41449385 | Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. |
| Q26799380 | Pharmacology and physiology of gastrointestinal enteroendocrine cells |
| Q89442826 | Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology |
| Q38811473 | SCFA Receptors in Pancreatic β Cells: Novel Diabetes Targets? |
| Q48293164 | SCFAs strongly stimulate PYY production in human enteroendocrine cells. |
| Q38059306 | Short chain fatty acids and their receptors: new metabolic targets |
| Q41854852 | Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets |
| Q90103525 | Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators |
| Q47886624 | Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q37643936 | The Influence of the Microbiome on Early-Life Severe Viral Lower Respiratory Infections and Asthma-Food for Thought? |
| Q102141675 | The N-terminus of GPR37L1 is proteolytically processed by matrix metalloproteases |
| Q38683793 | The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. |
| Q38121495 | The therapeutic potential of GPR43: a novel role in modulating metabolic health. |
| Q38249182 | Treatment of type 2 diabetes by free Fatty Acid receptor agonists |
| Q51377000 | Using Biosensors to Study Free Fatty Acid Receptor Pharmacology and Function. |
Search more.